A TGF-beta subtype that was originally identified as a GLIOBLASTOMA-derived factor which inhibits the antigen-dependent growth of both helper and CYTOTOXIC T LYMPHOCYTES. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta2 and TGF-beta2 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor.
Transforming Growth Factor Beta2 has been studied across 23 research domains including 🔬 Oncology, 👁️ Vision & Eye, 🦴 Bone & Joint, ✨ Skin & Hair, 🔬 Inflammation. The primary research focus is 🔬 Oncology with 21% of studies addressing this area.
This evidence profile for Transforming Growth Factor Beta2 is generated deterministically from 300 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.
Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.